Patent 7897619 was granted and assigned to Amgen on March, 2011 by the United States Patent and Trademark Office.
The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein.